The Biotech Sales & Distribution Associate will provide administrative support to the International Distribution team and BioLegend Distributors….From Biolegend – Wed, 08 Mar 2017 21:56:50 GMT – View all San Diego jobs
Kelly Scientific is seeking an Animal Technician. We have a number of open positions with our clients in San Diego. Seeking candidates with experience with cage wash, animal husbandry, and any mice or rate experience would be a bonus.
Please send re […
Please, apply through:
These exciting careers involve creative challenges of moving from theoretical abstractions to humane, practical clinical interventions that are needed to improve health care […
Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…From Ajinomoto Althea, Inc. – Wed, 08 Mar 2017 19:16:13 GMT – View all San Diego jobs
Experience with medical device or biotechnology company preferred. Illumina is seeking a ETQ Business System Analyst who will be responsible for the design,…From Illumina, Inc. – Wed, 08 Mar 2017 18:42:34 GMT – View all San Diego jobs
Cellics Therapeutics Inc. is a rapidly growing biotech company located in Sorrento Valley area. Cellics focuses on the development of novel therapeutics based on biomimetic cell membrane coated nanoparticles. Cellics offers a highly motivational and […
This opportunity positions the candidate in a leading edge segment of the Biotechnology field. We are seeking an experienced Software Test Engineer…. $25 – $50 an hourFrom Indeed – Wed, 08 Mar 2017 16:41:33 GMT – View all San Diego jobs
SAN DIEGO, March 8, 2017 /PRNewswire/ — StemCutis, LLC, which develops stem cell and stem cell factor products for treating skin conditions due to disease or environment, introduces a line of skincare products, the Synergy Collection. To restore the skin’s ability to fight the signs of aging, StemCutis Synergy products feature a cosmetic blend of stem cell factors and other natural ingredients.
StemCutis products use stem cell factors produced by mesenchymal stem cells, which are responsible for organ and tissue repair and for rejuvenation. Stem cells are obtained from healthy volunteers of approximately 18 years of age and, through proprietary methods, these cells are grown in low-oxygen conditions that greatly improve their potency. The stem cell factors produced by these cells are collected, purified and encapsulated in the Synergy products, which blend science and nature to give back the appearance and glow of a young adult’s skin.
The StemCutis Synergy Collection features Synergy EssenceTM, Synergy CreamTM and Synergy PatchesTM and is available for purchase at https://www.stemcutis.com/collections/all.
For smoother, brighter, healthier looking skin, the Synergy Essence is a potent serum of proprietary stem cell factors encapsulated in a nurturing fluid, plus nourishing vitamins and natural extracts. The Essence reduces the appearance of signs of aging and restores youthful glow. Use twice a day on face, neck and décolletage areas after cleansing.
The silky Synergy Cream can be used as a moisturizer for all skin types. These encapsulated stem cell factors in nurturing beads are combined with herbal ingredients to give skin a youthful, healthy glow. This unique formula provides a strong antioxidant defense for skin against the damaging effects of free radicals. Use twice a day on face, neck and hands alone or, for optimal results, after applying Synergy Essence.
For smoother, brighter and healthier looking skin, the StemCutis Synergy Patch is the only product available with the power of hyaluronic acid and StemCutis’ proprietary stem cell factor crystals. Each patch is a crystal delivery system that drives the potent ingredients into the skin for maximum benefit. For greatest results, use twice a week on clean, dry skin in areas of fine lines such as crow’s feet.
For more information and to purchase the products, please visit www.StemCutis.com.
About StemCutis, LLC
Founded in San Diego, California in 2014, StemCutis, LLC, a subsidiary of Stemedica Cell Technologies, Inc., is a global biotechnology company that develops stem cell-based dermatological therapies and over-the-counter (OTC) skin care products for dermatological applications. StemCutis therapies are based on the unique, proprietary technologies for the expansion of cells under hypoxic conditions, which provides critical benefits for safety, efficacy, scalability, and standardization. StemCutis has exclusive, worldwide licenses and rights from Stemedica and other Stemedica-related companies to develop and market the products for a range of conditions that affect skin and tissue appearance and function, such as compromised skin, hair loss, burns and hypertrophic, atrophic, and keloid scars, etc. For more information, visit www.stemcutis.com.
About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies, Inc. is a specialty biopharmaceutical company that manufactures best-in-class, allogeneic, adult stem cells and stem cell-derived factors. The company is a government-licensed manufacturer of cGMP, clinical-grade stem cells currently used in clinical trials in the United States under FDA Investigational New Drug (IND) approval for chronic heart failure, ischemic stroke and Alzheimer’s disease. Stemedica’s products are also used by research institutions and hospitals outside of US under the auspices of international regulatory authorities for pre-clinical and clinical (human) trials. Stemedica is developing clinical trials for other indications using its adult, allogeneic stem cells. The company has headquarters in San Diego, California, and can be found online at www.stemedica.com.
All media inquiries:
Jackie Townsend Konstanturos
The Townsend Team
SOURCE StemCutis, LLC
Bio2 Technologies, Inc. to Present Results from Ovine Spinal Fusion Study at the 2017 Orthopedic Research Society Meeting
A structural, resorbable interbody device constructed with Bio2’s proprietary Vitrium® orthobiomaterial demonstrates the capability for a total biologic fusion
WOBURN, Mass., March 8, 2017 /PRNewswire/ — Bio2 Technologies will present a poster at the Annual Meeting of the Orthopaedic Research Society (http://www.ors.org) in San Diego, CA on March 22, 2017 reporting the results from an ovine interbody fusion study conducted at Colorado State University comparing Bio2’s Vitrium device to an implant of similar design constructed from PEEK polymer. Autograft bone was placed in the central lumen of both devices.
Vitrium is an advanced orthobiomaterial with structural properties similar to cortical bone. It is composed of bioactive glass, a material with well-established osteostimulative properties. Bio2 has developed a proprietary manufacturing process to produce a strong, three-dimensional structure featuring interconnected pores facilitating the propagation of new bone.
The biomechanical tests (performed by mdevdev, San Francisco, CA) evaluated Vitrium’s ability to exhibit the ideal characteristics of a spinal fusion product, prospectively defined as: a) an effective, safe resorption/bone formation profile, b) stimulation of new bone formation to increase fusion rates, and c) sufficient strength to bear/share physiologic loads. Janet Krevolin, Ph.D., Bio2’s Chief Technical Officer and co-author of the poster, stated “the test results clearly demonstrated that Vitrium achieved these objectives. All subjects demonstrated a reduction in motion at 26 weeks indicating a fusion taking place for both the Vitrium and PEEK implants. Of note, in axial compressive load to failure testing the Vitrium fusion exhibited strength in excess of the adjoining vertebral bodies, whereas the PEEK fusion failed at the fusion site. The test data show the Vitrium devices exhibited the ideal characteristics of an interbody fusion product.”
Additional information on Vitrium and the ovine spinal fusion study may be found at: http://www.bio2tech.com
SOURCE Bio2 Technologies, Inc.
Molecular Assemblies Appoints Floyd E. Romesberg from The Scripps Research Institute to Scientific Advisory Board
SAN DIEGO, March 8, 2017 /PRNewswire/ — Molecular Assemblies, Inc., a company developing a proprietary enzymatic DNA synthesis technology designed to power the next generation of DNA-based products, today announced that it has appointed Floyd E. Romesberg, PhD, a renowned scientist and professor of chemistry at The Scripps Research Institute, to its scientific advisory board.
“We are extremely honored to have Dr. Romesberg join our team, as we build a world-class group of thought leaders to help us advance our enzymatic approach to DNA synthesis,” said Molecular Assemblies President and CEO Mike Kamdar. “Dr. Romesberg’s experience and guidance will be of great benefit as we advance our groundbreaking technology.”
Dr. Romesberg has managed a research group at The Scripps Research Institute since 1998. His group uses a broad range of techniques, including non-linear optical spectroscopy, organic chemistry, microbiology, and genetics, to study different aspects of evolution. This work has been described in more than 100 peer-reviewed publications. Dr. Romesberg is best known for developing unnatural base pairs for the expansion of the genetic alphabet and is also working to develop novel antibiotics, as well as to understand how evolution tailors protein dynamics and how cellular stress and DNA damage induce cell-cycle checkpoint responses and mutations. In January, The Scripps Research Institute announced that Dr. Romesberg and his team had developed the first stable semisynthetic organism, engineered for the stable expansion of the genetic alphabet. Their research was published online ahead of print in the journal Proceedings of the National Academy of Sciences. In addition to his work at The Scripps Research Institute, Dr. Romesberg is the scientific founder and a member of the board of directors of Synthorx. Prior to Synthorx, he served as the scientific co-founder and a member of the board of directors of RQx Pharmaceuticals (acquired by Genentech) and Achaogen. Dr. Romesberg received a Bachelor of Science degree in chemistry from The Ohio State University and a doctorate in physical organic chemistry from Cornell University.
“Molecular Assemblies’ enzymatic approach to DNA synthesis has the potential to significantly advance our ability to develop long, high-quality strands of DNA cost effectively, enabling us to achieve scientific breakthroughs more rapidly,” Dr. Romesberg said. “I’m very pleased to be collaborating with Molecular Assemblies to further develop this exciting technology.”
Molecular Assemblies Chief Scientific Officer and co-founder J. William Efcavitch added, “Dr. Romesberg’s internationally recognized expertise in non-natural nucleotides and their interaction with DNA polymerases will be of immense value to Molecular Assemblies, and we look forward to his contributions.”
About Molecular Assemblies
Molecular Assemblies, Inc. is a San Diego-based company focused on developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines and bio-based electronics. For more information please visit molecularassemblies.com.
Michael Kamdar, CEO
SOURCE Molecular Assemblies, Inc.